iBet uBet web content aggregator. Adding the entire web to your favor.

Link to original content: https://pubmed.ncbi.nlm.nih.gov/27573656/

Interleukin-10: An Immune-Activating Cytokine in Cancer Immunotherapy - PubMed

This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2016 Oct 10;34(29):3576-3578.

doi: 10.1200/JCO.2016.69.6435.

Interleukin-10: An Immune-Activating Cytokine in Cancer Immunotherapy

Hui Zhang¹, Yu Wang², E Shelley Hwang³, You-Wen He²

Affiliations

Affiliations

¹ First Affiliated Hospital, China Medical University, Shenyang, People's Republic of China.
² Duke University Medical Center, Durham, NC.
³ Duke University Comprehensive Cancer Center, Durham, NC.

PMID: 27573656
DOI: 10.1200/JCO.2016.69.6435

Comment

Interleukin-10: An Immune-Activating Cytokine in Cancer Immunotherapy

Hui Zhang et al. J Clin Oncol. 2016.

. 2016 Oct 10;34(29):3576-3578.

doi: 10.1200/JCO.2016.69.6435.

Authors

Hui Zhang¹, Yu Wang², E Shelley Hwang³, You-Wen He²

Affiliations

¹ First Affiliated Hospital, China Medical University, Shenyang, People's Republic of China.
² Duke University Medical Center, Durham, NC.
³ Duke University Comprehensive Cancer Center, Durham, NC.

PMID: 27573656
DOI: 10.1200/JCO.2016.69.6435

No abstract available

PubMed Disclaimer

Comment on

Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.
Naing A, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, Falchook GS, Pant S, Whiteside M, Rasco DR, Mumm JB, Chan IH, Bendell JC, Bauer TM, Colen RR, Hong DS, Van Vlasselaer P, Tannir NM, Oft M, Infante JR. Naing A, et al. J Clin Oncol. 2016 Oct 10;34(29):3562-3569. doi: 10.1200/JCO.2016.68.1106. J Clin Oncol. 2016. PMID: 27528724 Free PMC article. Clinical Trial.

Similar articles

The IL-2 cytokine family in cancer immunotherapy.
Sim GC, Radvanyi L. Sim GC, et al. Cytokine Growth Factor Rev. 2014 Aug;25(4):377-90. doi: 10.1016/j.cytogfr.2014.07.018. Epub 2014 Aug 1. Cytokine Growth Factor Rev. 2014. PMID: 25200249 Review.
Which immunological parameters are clinically essential to monitor IL-2 cancer immunotherapy?
Lissoni P, Brivio F, Viviani S, Fumagalli L. Lissoni P, et al. J Biol Regul Homeost Agents. 1999 Apr-Jun;13(2):110-4. J Biol Regul Homeost Agents. 1999. PMID: 10503734 Review.
Relation of pro- and anti-inflammatory cytokines and the production of nitric oxide in patients receiving high-dose immunotherapy with interleukin-2.
Locker GJ, Kofler J, Stoiser B, Wilfing A, Wenzel C, Wögerbauer M, Steger GG, Zielinski CC, Mader R, Burgmann H. Locker GJ, et al. Eur Cytokine Netw. 2000 Sep;11(3):391-6. Eur Cytokine Netw. 2000. PMID: 11022123 Clinical Trial.
Rationale for the utilization of interleukin-4, an immune-recognition induced cytokine, in cancer immunotherapy.
Costello R, Lipcey C, Olive D. Costello R, et al. Eur J Med. 1993 Jan;2(1):54-7. Eur J Med. 1993. PMID: 8258007 Review.
Targeted cytokines for cancer immunotherapy.
Lode HN, Reisfeld RA. Lode HN, et al. Immunol Res. 2000;21(2-3):279-88. doi: 10.1385/IR:21:2-3:279. Immunol Res. 2000. PMID: 10852128

See all similar articles

Cited by

Fighting Pancreatic Cancer with a Vaccine-Based Winning Combination: Hope or Reality?
Brugiapaglia S, Spagnolo F, Intonti S, Novelli F, Curcio C. Brugiapaglia S, et al. Cells. 2024 Sep 16;13(18):1558. doi: 10.3390/cells13181558. Cells. 2024. PMID: 39329742 Free PMC article. Review.
Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds.
Radanovic I, Klarenbeek N, Rissmann R, Groeneveld GJ, van Brummelen EMJ, Moerland M, Bosch JJ. Radanovic I, et al. Front Oncol. 2022 Aug 29;12:954806. doi: 10.3389/fonc.2022.954806. eCollection 2022. Front Oncol. 2022. PMID: 36106110 Free PMC article.
Profiling of immune features to predict immunotherapy efficacy.
Ye Y, Zhang Y, Yang N, Gao Q, Ding X, Kuang X, Bao R, Zhang Z, Sun C, Zhou B, Wang L, Hu Q, Lin C, Gao J, Lou Y, Lin SH, Diao L, Liu H, Chen X, Mills GB, Han L. Ye Y, et al. Innovation (Camb). 2021 Dec 2;3(1):100194. doi: 10.1016/j.xinn.2021.100194. eCollection 2022 Jan 25. Innovation (Camb). 2021. PMID: 34977836 Free PMC article.
Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy.
Apollonio B, Ioannou N, Papazoglou D, Ramsay AG. Apollonio B, et al. Front Oncol. 2021 Mar 25;11:626818. doi: 10.3389/fonc.2021.626818. eCollection 2021. Front Oncol. 2021. PMID: 33842331 Free PMC article. Review.
Retargeting of NK-92 Cells against High-Risk Rhabdomyosarcomas by Means of an ERBB2 (HER2/Neu)-Specific Chimeric Antigen Receptor.
Gossel LDH, Heim C, Pfeffermann LM, Moser LM, Bönig HB, Klingebiel TE, Bader P, Wels WS, Merker M, Rettinger E. Gossel LDH, et al. Cancers (Basel). 2021 Mar 22;13(6):1443. doi: 10.3390/cancers13061443. Cancers (Basel). 2021. PMID: 33809981 Free PMC article.

See all "Cited by" articles

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

Grants and funding

R21 AI119707/AI/NIAID NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations